Preclinical testing of Erlotinib in a transgenic alveolar rhabdomyosarcoma mouse model

Sarcoma

Volumn 2011, Issue , 2011, Pages

  Abraham, Jinu ^a   Nelon, Laura D ^b   Kubicek, Courtney B ^b   Kilcoyne, Aoife ^b,c   Hampton, Sheila T ^b   Zarzabal, Lee Ann ^b   Giles, Francis J ^c   Michalek, Joel E ^b   Rubin, Brian P ^d   Keller, Charles ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERLOTINIB; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GENE EXPRESSION; GENE FUSION; GENE INACTIVATION; MOUSE; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR CELL CULTURE; TUMOR GROWTH; WEIGHT REDUCTION;

EID: 79959349882     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2011/130484     Document Type: Article

References (16)

1. Arndt C. A. S., Crist W. M., Common musculoskeletal tumors of childhood and adolescence New England Journal of Medicine 1999 341 5 342 352
2. Breneman J. C., Lyden E., Pappo A. S., Link M. P., Anderson J. R., Parham D. M., Qualman S. J., Wharam M. D., Donaldson S. S., Maurer H. M., Meyer W. H., Baker K. S., Paidas C. N., Crist W. M., Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcomaa report from the Intergroup Rhabdomyosarcoma Study IV Journal of Clinical Oncology 2003 21 1 78 84
3. Williams B. A., Williams K. M., Doyle J., Stephens D., Greenberg M., Malkin D., Pappo A. S., Metastatic rhabdomyosarcoma: a retrospective review of patients treated at the hospital for sick children between 1989 and 1999 Journal of Pediatric Hematology/Oncology 2004 26 4 243 247 (Pubitemid 38500973)
4. Hochhaus A., O'Brien S. G., Guilhot F., Druker B. J., Branford S., Foroni L., Goldman J. M., Mller M. C., Radich J. P., Rudoltz M., Mone M., Gathmann I., Hughes T. P., Larson R. A., Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia Leukemia 2009 23 6 1054 1061
5. Quek R., George S., Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib Biologics 2009 4 19 31
6. Armistead P. M., Salganick J., Roh J. S., Steinert D. M., Patel S., Munsell M., El-Naggar A. K., Benjamin R. S., Zhang W., Trent J. C., Expression of receptor tyrosine kinases and apoptotic molecules in rhabdomyosarcoma: correlation with overall survival in 105 patients Cancer 2007 110 10 2293 2303 (Pubitemid 350100752)
7. Cen L., Arnoczky K. J., Hsieh F. C., Lin H. J., Qualman S. J., Yu S., Xiang H., Lin J., Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma Modern Pathology 2007 20 9 936 946 (Pubitemid 47267820)
8. Lurje G., Lenz H. J., EGFR signaling and drug discovery Oncology 2009 77 400 410
9. Shepherd F. A., Pereira J. R., Ciuleanu T., Eng H. T., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., Van Kooten M., Dediu M., Findlay B., Tu D., Johnston D., Bezjak A., Clark G., Santabrbara P., Seymour L., Erlotinib in previously treated non-small-cell lung cancer New England Journal of Medicine 2005 353 2 123 132 (Pubitemid 41058344)
10. Keller C., Arenkiel B. R., Coffin C. M., El-Bardeesy N., DePinho R. A., Capecchi M. R., Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function Genes and Development 2004 18 21 2614 2626 (Pubitemid 39453101)
11. Keller C., Hansen M. S., Coffin C. M., Capecchi M. R., Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin Genes and Development 2004 18 21 2608 2613 (Pubitemid 39453100)
12. Nishijo K., Chen Q. R., Zhang L., McCleish A. T., Rodriguez A., Cho M. J., Prajapati S. I., Gelfond J. A. L., Chisholm G. B., Michalek J. E., Aronow B. J., Barr F. G., Randall R. L., Ladanyi M., Qualman S. J., Rubin B. P., LeGaIIo R. D., Wang C., Khan J., Keller C., Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma Cancer Research 2009 69 7 2902 2911
13. Higgins B., Kolinsky K., Smith M., Beck G., Rashed M., Adames V., Linn M., Wheeldon E., Gand L., Birnboeck H., Hoffmann G., Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models Anti-Cancer Drugs 2004 15 5 503 512 (Pubitemid 38736950)
14. Moyer J. D., Barbacci E. G., Iwata K. K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M. J., Moyer M. P., Neveu M., Pollack V. A., Pustilnik L. R., Reynolds M. M., Sloan D., Theleman A., Miller P., Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Research 1997 57 21 4838 4848 (Pubitemid 27468992)
15. Moore M. J., Goldstein D., Hamm J., Figer A., Hecht J. R., Gallinger S., Au H. J., Murawa P., Walde D., Wolff R. A., Campos D., Lim R., Ding K., Clark G., Voskoglou-Nomikos T., Ptasynski M., Parulekar W., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group Journal of Clinical Oncology 2007 25 15 1960 1966 (Pubitemid 46972777)
16. Jakacki R. I., Hamilton M., Gilbertson R. J., Blaney S. M., Tersak J., Krailo M. D., Ingle A. M., Voss S. D., Dancey J. E., Adamson P. C., Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a children's oncology group phase I consortium study Journal of Clinical Oncology 2008 26 30 4921 4927